Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL-001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic-Lymphocytic-Leukemia

被引：0

作者：

Wendtner, Clemens M. ^{[1
]}

Mahadevan, Daruka ^{[2
]}

Stilgenbauer, Stephan ^{[3
]}

Frankfurt, Olga ^{[4
]}

Bloor, Adrian ^{[5
]}

Bosch, Francesc ^{[6
]}

Uharek, Lutz ^{[7
]}

Furman, Richard R. ^{[8
]}

Gobbi, Marco ^{[9
]}

Gribben, John G. ^{[10
]}

Kimby, Eva K. ^{[11
]}

Sekeres, Mikkael A. ^{[12
]}

Cripe, Larry D. ^{[13
]}

Lombardy, Elyane ^{[14
]}

Shah, Sheetal ^{[14
]}

Moutouh-de Parseval, Laure A. ^{[14
]}

Chanan-Khan, Asher Alban ^{[15
]}

Knight, Robert D. ^{[14
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[2] Arizona Canc Ctr, Tucson, AZ USA

[3] Univ Ulm, Ulm, Germany

[4] NW Mem Hosp, Robert H Lurie CCC, Chicago, IL 60611 USA

[5] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[6] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[7] Charite Univ Med Berlin, Med Clin Hematol Oncol 3, Berlin, Germany

[8] Weill Cornell Med Coll, Dept Hematol Oncol, New York, NY USA

[9] Univ Genova Italy, Genoa, Italy

[10] Barts & London Queen Marys Sch Med & Dent, London, England

[11] Karolinska Inst, Hematol Ctr, Stockholm, Sweden

[12] Cleveland Clin, Cleveland, OH 44106 USA

[13] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[14] Celgene Corp, Summit, NJ USA

[15] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：732 / 732

页数：1

共 50 条

[21] A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and IV Bortezomib in Patients with Relapsed Multiple Myeloma.
San-Miguel, Jesus F.
Sezer, Orhan
Siegel, David
Guenther, Andreas
Mateos, Maria-Victoria
Prosser, Ian
Cavo, Michele
Blade, Joan
Boccadoro, Mario
Bengoudifa, Bourras R.
Klebsattel, Martin
Bourquelot, Priscille M.
Anderson, Kenneth C.
[J]. BLOOD, 2009, 114 (22) : 1481 - 1482
[22] Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
David M. Loeb
Ji Won Lee
Daniel A. Morgenstern
Yvan Samson
Anne Uyttebroeck
Chuhl Joo Lyu
An Van Damme
Karsten Nysom
Margaret E. Macy
Alexandra P. Zorzi
Julia Xiong
Petra Pollert
Ingrid Joerg
Yulia Vugmeyster
Mary Ruisi
Hyoung Jin Kang
[J]. Cancer Immunology, Immunotherapy, 2022, 71 : 2485 - 2495
[23] Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
Loeb, David M.
Lee, Ji Won
Morgenstern, Daniel A.
Samson, Yvan
Uyttebroeck, Anne
Lyu, Chuhl Joo
Van Damme, An
Nysom, Karsten
Macy, Margaret E.
Zorzi, Alexandra P.
Xiong, Julia
Pollert, Petra
Joerg, Ingrid
Vugmeyster, Yulia
Ruisi, Mary
Kang, Hyoung Jin
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (10) : 2485 - 2495
[24] Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
San-Miguel, Jesus
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Liu, Kevin
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Luo, Man
Farnsworth, Andrew
Nahi, Hareth
Chari, Ajai
[J]. HAEMATOLOGICA, 2021, 106 (06) : 1725 - 1732
[25] SQ3370-001 IS A MULTI-CENTER OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO TEST A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO TREAT ADVANCED SOLID TUMORS
Bhadri, Vivek
Bui, Nam
Guminski, Alexander
Oneto, Jose Mejia
Murthy, Ravi
Sankhala, Kamalesh
Saville, M. Wayne
Srinivasan, Sangeetha
Steffner, Robert
Subbiah, Vivek
Wang, Ding
Yee, Nathan
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A253 - A254
[26] Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia
O'Brien, Maureen M.
Alonzo, Todd A.
Cooper, Todd M.
Levine, John E.
Brown, Patrick A.
Slone, Tamra
August, Keith J.
Benettaib, Bouchra
Biserna, Noha
Poon, Jennifer
Patturajan, Meera
Chen, Nianhang
Simcock, Mathew
Zimmerman, Linda
Kolb, E. Anders
[J]. PEDIATRIC BLOOD & CANCER, 2021, 68 (07)
[27] Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Burris, Howard A., III
Flinn, Ian W.
Patel, Manish R.
Fenske, Timothy S.
Deng, Changchun
Brander, Danielle M.
Gutierrez, Martin
Essell, James H.
Kuhn, John G.
Miskin, Hari P.
Sportelli, Peter
Weiss, Michael S.
Vakkalanka, Swaroop
Savona, Michael R.
O'Connor, Owen A.
[J]. LANCET ONCOLOGY, 2018, 19 (04): : 486 - 496
[28] A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma
Shah, Nina D.
Turtle, Cameron J.
Cowan, Andrew J.
Chavez, Julio C.
Budde, Lihua E.
Marcondes, Mario Q.
Lee, Zachary
Lin, Wei
Zalevsky, Jonathan
Tagliaferri, Mary
Patel, Krina K.
[J]. BLOOD, 2019, 134
[29] A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)
Zwaan, C. Michel
Soderhall, Stefan
Brethon, Benoit
Luciani, Matteo
Rizzari, Carmelo
Sternberg, David
Besse, Emmanuelle
Dutreix, Catherine
Fagioli, Franca
Ho, Phoenix
Dufour, Carlo
Pieters, Rob
[J]. BLOOD, 2015, 126 (23)
[30] Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies
Siegel, David S.
McDonald, Andrew
Novitzky, Nicolas
Bensinger, William
Craig, Michael
van Rhee, Frits
Gutierrez, Martin
Libby, Edward N.
Thompson, John
Bexon, Alice S.
Barranco, Charles
Taylor, Catherine A.
Dondero, Richard
Browne, Leslie J.
Kurman, Michael R.
Lust, John A.
[J]. BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →